US 7,429,653 B2
	Stabilized soluble glycoprotein trimers
Joseph G. Sodroski, Medford, Mass. (US); Richard Wyatt, Andover, Mass. (US); Xinzhen Yang, Allston, Mass. (US); Michael Farzan, Brookline, Mass. (US); and Peter D. Kwong, Washington, D.C. (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, Mass. (US)
Filed on May 11, 2005, as Appl. No. 11/126,797.
Application 11/126797 is a division of application No. 10/100534, filed on Mar. 18, 2002, granted, now 6,911,205.
Application 10/100534 is a continuation of application No. PCT/US00/25557, filed on Sep. 18, 2000.
Claims priority of provisional application 60/154677, filed on Sep. 17, 1999.
Prior Publication US 2005/0220817 A1, Oct. 06, 2005
Int. Cl. A61K 39/00 (2006.01)

U.S. Cl. 536—23.4  [424/185.1; 424/192.1; 424/208.1; 530/300]

10 Claims

1. An isolated molecule containing a nucleotide sequence encoding an HIV-1 or HIV-2 gp125 monomer, referred to as a gp120 monomer, wherein the gp120 monomers form a stable trimer, wherein the nucleic acid sequence encoding at least one of the gp120 monomers has been modified from the wildtype sequence to encode a modified gp120 monomer, wherein the modified gp120 monomer maintains the overall three-dimensional structure of the wildtype gp120, wherein a portion of one variable region has been deleted, and wherein a trimeric motif has been added carboxyl to the gp120 monomer's carboxyl terminus.